文献速递湿疹皮炎与荨麻疹

Tralokinumab治疗中重度特应性皮炎:两项52周III期试验结果

Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
PubMed 文献 · Br J Dermatol · 2020-12-30

ECZTRA 1和ECZTRA 2两项52周随机双盲安慰剂对照III期试验评估了Tralokinumab单药治疗中重度特应性皮炎成人患者的疗效与安全性。第16周时,Tralokinumab组达到IGA 0/1和EASI 75的患者比例显著高于安慰剂组,且瘙痒等症状早期改善,多数应答者维持至第52周,耐受性良好。

要点

  • Tralokinumab单药在中重度AD中第16周疗效优于安慰剂。
  • 早期改善瘙痒、睡眠干扰及生活质量。
  • 多数第16周应答者持续治疗至第52周维持应答。

核心结论

  • Tralokinumab单药治疗16周疗效优于安慰剂,且耐受性良好至52周。

研究设计与样本

  • 两项52周、随机、双盲、多中心、安慰剂对照III期试验(ECZTRA 1和ECZTRA 2)。
  • 中重度AD成人按3:1随机接受皮下Tralokinumab 300 mg每2周或安慰剂。
  • 第16周应答者再随机接受Tralokinumab每2周、每4周或安慰剂治疗36周。

主要发现

  • 首次基线后测量即观察到瘙痒、睡眠干扰、DLQI、SCORAD和POEM的早期改善。
  • 第16周Tralokinumab应答者中多数在第52周持续治疗且无需救援药物(包括外用糖皮质激素)维持应答。

临床怎么用

  • Tralokinumab单药可作为中重度AD外用治疗应答不足患者的治疗选择。
  • 治疗16周评估IGA 0/1和EASI 75应答,应答者可继续治疗并长期维持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In phase II studies, tralokinumab combined with topical corticosteroids provided early and sustained improvements in AD signs and symptoms. OBJECTIVES: To evaluate the efficacy and safety of tralokinumab monotherapy in adults with moderate-to-severe AD who had an inadequate response to topical treatments. METHODS: In two 52-week, randomized, double-blind, placebo-controlled, phase III trials, ECZTRA 1 and ECZTRA 2, adults with moderate-to-severe AD were randomized (3 : 1) to subcutaneous tralokinumab 300 mg every 2 weeks (Q2W) or placebo. Primary endpoints were Investigator's Global Assessment (IGA) score of 0 or 1 at week 16 and ≥ 75% improvement in Eczema Area and Severity Index (EASI 75) at week 16. Patients achieving an IGA score of 0 or 1 and/or EASI 75 with tralokinumab at week 16 were rerandomized to tralokinumab Q2W or every 4 weeks or placebo, for 36 weeks. The trials were registered with ClinicalTrials.gov: NCT03131648 and NCT03160885. RESULTS: At week 16, more patients who received tralokinumab vs. placebo achieved an IGA score of 0 or 1: 15·8% vs. 7·1% in ECZTRA 1 [difference 8·6%, 95% confidence interval (CI) 4·1-13·1; P = 0·002] and 22·2% vs. 10·9% in ECZTRA 2 (11·1%, 95% CI 5·8-16·4; P < 0·001) and EASI 75: 25·0% vs. 12·7% (12·1%, 95% CI 6·5-17·7; P < 0·001) and 33·2% vs. 11·4% (21·6%, 95% CI 15·8-27·3; P < 0·001). Early improvements in pruritus, sleep interference, Dermatology Life Quality Index, SCORing Atopic Dermatitis and Patient-Oriented Eczema Measure were observed from the first postbaseline measurements. The majority of week 16 tralokinumab responders maintained response at week 52 with continued tralokinumab treatment without any rescue medication (including topical corticosteroids). Adverse events were reported in 76·4% and 61·5% of patients receiving tralokinumab in ECZTRA 1 and ECZTRA 2, respectively, and in 77·0% and 66·0% of patients receiving placebo in ECZTRA 1 and ECZTRA 2, respectively, in the 16-week initial period. CONCLUSIONS: Tralokinumab monotherapy was superior to placebo at 16 weeks of treatment and was well tolerated up to 52 weeks of treatment.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2020. PMID: 33000465. doi:10.1111/bjd.19574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。